Sanofi (SNY) said Friday the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma adult patients eligible for autologous stem cell transplant.
The approval followed a positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use last month, the company said.
Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility, Sanofi said.
Price: 49.91, Change: -0.22, Percent Change: -0.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.